At the 16th World Conference on Lung Cancer in Denver last week, companies big and small presented data for their lung cancer drug candidates. While immuno-oncology is the sexy new technology moving into lung cancer, plenty of other strategies are being used to keep tumors at bay.
Without a doubt, wet age-related macular degeneration (AMD) has been a lucrative market for companies. Regeneron Pharmaceuticals Inc. announced $1.2 billion in U.S. sales of Eylea (aflibercept) in the first half of 2015, and Roche AG posted CHF769 million (US$804 million) in U.S. sales of Lucentis (ranibizumab).
Carcinoembryonic antigen (CEA) was one of the first oncoproteins discovered a half century ago. The protein is expressed in a subset of most epithelial cancers, including non-small-cell lung cancer, colorectal, pancreas, breast, gastric and medullary thyroid cancers. Globeimmune Inc. estimates that CEA is overexpressed in approximately 500,000 new cancer cases in the U.S. each year.
Every drug company wants to get the best price for its drugs, but that's easier said than done, especially in the current environment with payers pushing back at high drug prices and pitting companies against each other to compete on price.
CGRP stands for calcitonin gene-related peptide but it might double for "could get really profitable" if drug companies targeting CGRP and its associated receptor are successful.
It wasn't the perfect second quarter, but we'll take it. You'll recall, U.S. investments in private companies tracked by BioWorld in the first quarter of the year started off like gangbusters, more than doubling the funding in the year-ago quarter. IPOs, on the other hand, left something to be desired.
The hemophilia drug market is well established with multiple drugs designed to replace the underlying deficiency: factor VIII for hemophilia A and factor IX for hemophilia B.
Those forward-looking disclosures management reads at the beginning of presentations and the risk factors listed in their SEC filings are often viewed by investors as standard lawyer-speak to cover the company from potential lawsuits should something bad happen.
Investors wanting to buy into the high-growth biotech industry without purchasing shares of individual companies have had limited choices of exchange traded funds (ETFs).
